semaglutide fda ban on Compounded GLP-1 Drugs: What to Know The FDA Just Banned Compounded

An exploratory analysis of genetic data of patients from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial showed that different haplotypes encoding for GLP-1R correlated with variable response rates to antipsychotic medications 132

Last years ad centered heavily on the brand providing access to compounded GLP-1 weight-loss drugs, prompting a backlash and debate around telehealth marketing and the boundaries of pharmaceutical advertising

Clinical trials consistently show weight loss of 1520% or more with GLP-1s, compared to 510% with medications like Contrave, orlistat, and phentermine

These medicines mimic the action of the naturally occurring GLP-1 hormone, which is released by the intestine in response to food intake